Information contained on this page is provided by companies via press release distributed through PR Newswire, an independent third-party content provider. PR Newswire, WorldNow and this Station make no warranties or representations in connection therewith.
HARTFORD, Conn., March 4, 2013 /PRNewswire/ -- Genomas®, a biomedical company delivering personalized medicine to modern clinical practice, has been awarded clinical laboratory licenses in three of the most populous States. The company's Laboratory of Personalized Health received licenses from the New York Department of Health, the Florida Agency for Health Care Administration, and the California Department of Public Health.
Gualberto Ruano, M.D., Ph.D., President of Genomas and Director of the Laboratory of Personalized Health (LPH) stated: "New York, Florida, and California are among the most demanding States in terms of laboratory technical expertise and business credentialing. Now we are determined to bring our clinical pharmacogenetics services to the people of these States and the entire nation." These key markets herald a national platform for Genomas products in personalized healthcare, medical decision-support and clinical genomic diagnostics.
LPH was certified previously by the Centers for Medicare and Medicaid Services (CMS) under CLIA (Clinical Laboratory Improvement Amendments, and was licensed by the CT Department of Public Health in 2005. In 2012, Genomas had attained credentialing as a Medicare provider and began providing services in Texas and Pennsylvania.
More than 500 clinicians and 5000 patients in Connecticut have already benefited from the Genomas HILOmet PhyzioType® System, which allows personalized management of over 250 drugs to treat mental illness, pain, diabetes, and heart disease. Clinicians access the information through the Personalized Health Portal, which is a secure web-based interface providing data on over 250 different medications. The clinical support extends to 130 neuro-psychiatric drugs (antidepressants, neuroleptics, anticonvulsants, anxiolytics, stimulants, analgesics, hypnotics) and 120 cardio-metabolic drugs (to treat hypertension, diabetes, angina, thrombosis, gastro-esophageal reflux disease, erectile dysfunction, asthma).
In CT, Genomas has established a successful distribution and customer support partnership with Clinical Laboratory Partners (CLP). James Fantus, President and CEO of CLP, and Vice President of Hartford Healthcare Corporation, commented: "It is a great satisfaction to witness a national platform developing through Genomas from Hartford Healthcare partnerships, which include Clinical Laboratory Partners, Hartford Hospital, Institute of Living, and Hospital of Central Connecticut. Genomas is leading Connecticut to national prominence in the clinical practice of personalized medicine."
Please visit www.genomas.com for more information.
©2012 PR Newswire. All Rights Reserved.